Oncol-话题@MedSci

#Oncol#

2384篇内容 | 2440人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1866481, encodeId=15ab186648197, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：TACE联合AC（阿帕替尼+卡瑞利珠单抗）较AC治疗改善不可切除肝细胞癌（HCC）患者的预后, objectType=article, longId=295066, objectId=890729506606, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=890729506606, replyNumber=0, likeNumber=81, createdTime=2022-10-31, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=890729506606, moduleTitle=Front Oncol：TACE联合AC（阿帕替尼+卡瑞利珠单抗）较AC治疗改善不可切除肝细胞癌（HCC）患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=890729506606)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866418, encodeId=2ab6186641815, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：高危因素是dMMR/MSI-H II期结肠癌的预后因素, objectType=article, longId=292097, objectId=1fde29209ebe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fde29209ebe, replyNumber=0, likeNumber=60, createdTime=2022-06-07, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fde29209ebe, moduleTitle=Front Oncol：高危因素是dMMR/MSI-H II期结肠癌的预后因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fde29209ebe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866496, encodeId=16761866496d7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：尼拉帕利在DNA修复基因缺陷的转移性去势抵抗性前列腺癌中的抗肿瘤活性, objectType=article, longId=295173, objectId=79422951e301, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79422951e301, replyNumber=0, likeNumber=75, createdTime=2022-05-12, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79422951e301, moduleTitle=Lancet Oncol：尼拉帕利在DNA修复基因缺陷的转移性去势抵抗性前列腺癌中的抗肿瘤活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=79422951e301)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866153, encodeId=d215186615355, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncology：癌症患者的希望之光，万能靶向药再出手，可降低78%疾病进展与死亡危险！, objectType=article, longId=214170, objectId=8d5e2141e01b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d5e2141e01b, replyNumber=0, likeNumber=83, createdTime=2021-08-21, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d5e2141e01b, moduleTitle=Lancet Oncology：癌症患者的希望之光，万能靶向药再出手，可降低78%疾病进展与死亡危险！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d5e2141e01b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866463, encodeId=62ba186646314, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：PD-L1高表达是肝细胞癌患者手术切除后索拉非尼辅助治疗后复发的独立预测因素, objectType=article, longId=294335, objectId=1c8d29433575, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c8d29433575, replyNumber=0, likeNumber=86, createdTime=2022-05-30, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c8d29433575, moduleTitle=Front Oncol：PD-L1高表达是肝细胞癌患者手术切除后索拉非尼辅助治疗后复发的独立预测因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c8d29433575)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866403, encodeId=190018664033e, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：原发肿瘤大小对结直肠癌（CRC）生存的预测和预后影响, objectType=article, longId=264983, objectId=effd2649830c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=effd2649830c, replyNumber=0, likeNumber=74, createdTime=2022-08-11, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=effd2649830c, moduleTitle=Front Oncol：原发肿瘤大小对结直肠癌（CRC）生存的预测和预后影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=effd2649830c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866477, encodeId=6a4018664e7e7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：原发灶无症状的结肠癌伴有同时性无法切除转移的患者中，使用化疗后进行原发灶切除（PTR）并不能改善预后, objectType=article, longId=295063, objectId=a41729506373, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a41729506373, replyNumber=0, likeNumber=89, createdTime=2022-05-30, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a41729506373, moduleTitle=Front Oncol：原发灶无症状的结肠癌伴有同时性无法切除转移的患者中，使用化疗后进行原发灶切除（PTR）并不能改善预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a41729506373)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866391, encodeId=6ebc186639107, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：Poziotinib治疗既往经治的晚期或转移性NSCLC患者的疗效和安全性, objectType=article, longId=221412, objectId=45d222141221, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45d222141221, replyNumber=0, likeNumber=105, createdTime=2022-02-13, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45d222141221, moduleTitle=J Clin Oncol：Poziotinib治疗既往经治的晚期或转移性NSCLC患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45d222141221)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866261, encodeId=3e1e1866261e1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：李琦团队研究中药配方PRM1201联合化疗辅助治疗III期结肠癌患者的疗效：随机、双盲、安慰剂对照研究, objectType=article, longId=217998, objectId=6a9321e99823, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a9321e99823, replyNumber=0, likeNumber=77, createdTime=2022-04-17, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a9321e99823, moduleTitle=Front Oncol：李琦团队研究中药配方PRM1201联合化疗辅助治疗III期结肠癌患者的疗效：随机、双盲、安慰剂对照研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a9321e99823)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866198, encodeId=24a7186619834, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：Venetoclax+达雷木单抗+地塞米松±硼替佐米可有效治疗复发/难治性多发性骨髓瘤！, objectType=article, longId=215765, objectId=00d1215e657e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00d1215e657e, replyNumber=0, likeNumber=68, createdTime=2022-06-18, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00d1215e657e, moduleTitle=J Clin Oncol：Venetoclax+达雷木单抗+地塞米松±硼替佐米可有效治疗复发/难治性多发性骨髓瘤！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00d1215e657e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866467, encodeId=360e186646e5e, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：EGFR突变NSCLC伴有脑膜转移(LM)的特征以及临床预后, objectType=article, longId=294584, objectId=1bcb294584df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bcb294584df, replyNumber=0, likeNumber=67, createdTime=2022-12-20, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bcb294584df, moduleTitle=Front Oncol：EGFR突变NSCLC伴有脑膜转移(LM)的特征以及临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1bcb294584df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866091, encodeId=72ed1866091c6, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：杜鲁伐单抗联合立体定向放疗明显改善早期NSCLC患者预后, objectType=article, longId=211558, objectId=a63921155892, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a63921155892, replyNumber=0, likeNumber=75, createdTime=2022-03-08, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a63921155892, moduleTitle=Lancet Oncol：杜鲁伐单抗联合立体定向放疗明显改善早期NSCLC患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a63921155892)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866095, encodeId=a651186609573, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Eur Urol Oncol：肾癌和膀胱癌中无细胞和循环肿瘤DNA的临床应用, objectType=article, longId=211751, objectId=7e4d211e518a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e4d211e518a, replyNumber=0, likeNumber=95, createdTime=2021-12-31, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e4d211e518a, moduleTitle=Eur Urol Oncol：肾癌和膀胱癌中无细胞和循环肿瘤DNA的临床应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e4d211e518a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866066, encodeId=6a871866066f3, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：DLBCL患者诊断-治疗间隔时间越短，基础肿瘤负荷可能越高！, objectType=article, longId=210699, objectId=0bbd21069923, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bbd21069923, replyNumber=0, likeNumber=87, createdTime=2021-07-22, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bbd21069923, moduleTitle=J Clin Oncol：DLBCL患者诊断-治疗间隔时间越短，基础肿瘤负荷可能越高！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bbd21069923)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866473, encodeId=1a9618664e3fe, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：使用18F-FDG PET/CT鉴别异位库欣综合征患者分泌促肾上腺皮质激素的肺部肿瘤, objectType=article, longId=294848, objectId=f54f29484825, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f54f29484825, replyNumber=0, likeNumber=78, createdTime=2022-06-03, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f54f29484825, moduleTitle=Front Oncol：使用18F-FDG PET/CT鉴别异位库欣综合征患者分泌促肾上腺皮质激素的肺部肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f54f29484825)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866456, encodeId=096b1866456bb, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ther Adv Med Oncol：国内多中心头对头III期研究发现转移性结直肠癌患者二线FOLFIRI方案并不优于单药伊立替康治疗，反而毒性增加, objectType=article, longId=294046, objectId=01c32940469c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01c32940469c, replyNumber=0, likeNumber=89, createdTime=2022-06-29, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01c32940469c, moduleTitle=Ther Adv Med Oncol：国内多中心头对头III期研究发现转移性结直肠癌患者二线FOLFIRI方案并不优于单药伊立替康治疗，反而毒性增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01c32940469c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866267, encodeId=a57b186626e69, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=The Oncologist： FTD/TPI和瑞戈非尼治疗晚期结直肠癌患者疗效对比, objectType=article, longId=218080, objectId=e0d821808039, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0d821808039, replyNumber=0, likeNumber=71, createdTime=2022-01-18, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0d821808039, moduleTitle=The Oncologist： FTD/TPI和瑞戈非尼治疗晚期结直肠癌患者疗效对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0d821808039)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866120, encodeId=96b318661201c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Eur Urol Oncol：非肌层浸润性膀胱癌患者的长期随访及与主动监测失败相关的因素 , objectType=article, longId=212985, objectId=800a21298528, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=800a21298528, replyNumber=0, likeNumber=80, createdTime=2021-11-07, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=800a21298528, moduleTitle=Eur Urol Oncol：非肌层浸润性膀胱癌患者的长期随访及与主动监测失败相关的因素 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=800a21298528)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866069, encodeId=b31d1866069f9, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Thorac Oncol：纳米-紫杉醇 vs 多西他赛治疗晚期NSCLC患者的疗效, objectType=article, longId=210739, objectId=ba42210e39c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba42210e39c8, replyNumber=0, likeNumber=81, createdTime=2021-08-07, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba42210e39c8, moduleTitle=J Thorac Oncol：纳米-紫杉醇 vs 多西他赛治疗晚期NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba42210e39c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866096, encodeId=ec55186609604, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncology：局部晚期头颈肿瘤的放化疗：一项个体患者数据网状荟萃分析 , objectType=article, longId=211726, objectId=629e211e265b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=629e211e265b, replyNumber=0, likeNumber=89, createdTime=2022-02-24, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=629e211e265b, moduleTitle=Lancet Oncology：局部晚期头颈肿瘤的放化疗：一项个体患者数据网状荟萃分析 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=629e211e265b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Oncol

2020-05-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：TACE联合AC（阿帕替尼+卡瑞利珠单抗）较AC治疗改善不可切除肝细胞癌（HCC）患者的预后

2022-10-31

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：高危因素是dMMR/MSI-H II期结肠癌的预后因素

2022-06-07

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：尼拉帕利在DNA修复基因缺陷的转移性去势抵抗性前列腺癌中的抗肿瘤活性

2022-05-12

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncology：癌症患者的希望之光，万能靶向药再出手，可降低78%疾病进展与死亡危险！

2021-08-21

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：PD-L1高表达是肝细胞癌患者手术切除后索拉非尼辅助治疗后复发的独立预测因素

2022-05-30

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：原发肿瘤大小对结直肠癌（CRC）生存的预测和预后影响

2022-08-11

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：原发灶无症状的结肠癌伴有同时性无法切除转移的患者中，使用化疗后进行原发灶切除（PTR）并不能改善预后

2022-05-30

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：Poziotinib治疗既往经治的晚期或转移性NSCLC患者的疗效和安全性

2022-02-13

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：李琦团队研究中药配方PRM1201联合化疗辅助治疗III期结肠癌患者的疗效：随机、双盲、安慰剂对照研究

2022-04-17

docwu2019 (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：Venetoclax+达雷木单抗+地塞米松±硼替佐米可有效治疗复发/难治性多发性骨髓瘤！

2022-06-18

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：EGFR突变NSCLC伴有脑膜转移(LM)的特征以及临床预后

2022-12-20

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：杜鲁伐单抗联合立体定向放疗明显改善早期NSCLC患者预后

2022-03-08

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Eur Urol Oncol：肾癌和膀胱癌中无细胞和循环肿瘤DNA的临床应用

2021-12-31

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：DLBCL患者诊断-治疗间隔时间越短，基础肿瘤负荷可能越高！

2021-07-22

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：使用18F-FDG PET/CT鉴别异位库欣综合征患者分泌促肾上腺皮质激素的肺部肿瘤

2022-06-03

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ther Adv Med Oncol：国内多中心头对头III期研究发现转移性结直肠癌患者二线FOLFIRI方案并不优于单药伊立替康治疗，反而毒性增加

2022-06-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

The Oncologist： FTD/TPI和瑞戈非尼治疗晚期结直肠癌患者疗效对比

2022-01-18

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Eur Urol Oncol：非肌层浸润性膀胱癌患者的长期随访及与主动监测失败相关的因素

2021-11-07

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Thorac Oncol：纳米-紫杉醇 vs 多西他赛治疗晚期NSCLC患者的疗效

2021-08-07

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncology：局部晚期头颈肿瘤的放化疗：一项个体患者数据网状荟萃分析

2022-02-24

科室
- - 订阅+
  - 更多科室
工具
服务